The Novel RSV Vaccine: Part 1

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and hospitalizations in children and older adults. A search for a vaccine may finally be over. Join host, Geoff Wall, and guest, Jake Galdo, as they dive into part 1 of a two-part series examining new research on the proposed RSV vaccine.The GameChangerRSV, COVID-19, and influenza are major disease burdens on children and older adults. Fortunately, COVID-19 and influenza have widely available vaccines – and maybe soon for RSV. A recent study of the mRNA vaccine in older adults improves antibody titers. Show Segments 00:00 - Introductions03:06 - Barriers to Development of the RSV Vaccine06:46 - Looking at the RSV Vaccine Study13:01 - The GameChanger: The Vaccine Outcomes20:57 - Connecting to Practice: The Potential Future of This Vaccine28:19 - Closing RemarksHostGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthGuestJake Galdo, PharmD, MBA, BCPS, BCGPManaging Network Facilitator, CPESN Health EquityCEO, SeguridadReferences and ResourcesFalsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. PMID: 15858184.Pharmacist Members, REDEEM YOUR CPE HERE!Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe barriers to development of an RSV vaccine2. Discuss outcomes of an RSV vaccines in older adults0.05 CEU/0.5 HrUAN: 0107-0000-23-192-H06-PInitial release date: 05/01/2023Expiration date: 05/01/2024Follow CEimpact on Social Media:LinkedInInstagram